Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 13/20 | 0.51 |
| ▸ | PSEN2 | P49810 | 13/20 | 0.51 |
| ▸ | APH1B | Q8WW43 | 13/20 | 0.51 |
| ▸ | NCSTN | Q92542 | 13/20 | 0.51 |
| ▸ | APH1A | Q96BI3 | 13/20 | 0.51 |
| ▸ | PSENEN | Q9NZ42 | 13/20 | 0.51 |
| ▸ | APP | P05067 | 1/20 | 0.48 |
| ▸ | AURKA | O14965 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2949979 | 0.86 | PSEN1 (0.53) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2951364 | 0.86 | PSEN1 (0.53) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2947897 | 0.83 | PSEN1 (0.52) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8244289 | 0.82 | APP (0.47) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL917304 | 0.81 | PSEN1 (0.56) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL918237 | 0.77 | PSEN1 (0.56) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL917479 | 0.77 | PSEN1 (0.53) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2950894 | 0.74 | PSEN1 (0.51) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL917589 | 0.74 | PSEN1 (0.58) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL917423 | 0.73 | PSEN1 (0.56) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7345056-B2 | Bridged N-cyclic sulfonamido inhibitors of gamma secretase | ELAN PHARMACEUTICALS, INC. (US) | 2008-03-18 | — | — | US | claimed |
| US-20070049612-A1 | Bridged N-Cyclic Sulfonamido Inhibitors of Gamma Secretase | ELAN PHARMACEUTICALS, INC. | 2007-03-01 | — | — | US | claimed |
| US-7754712-B2 | Bridged N-cyclic sulfonamido inhibitors of gamma secretase | ELAN PHARMACEUTICALS, INC. (US) | 2010-07-13 | — | — | US | disclosed |
| US-7754712-B2 | Bridged N-cyclic sulfonamido inhibitors of gamma secretase | ELAN PHARMACEUTICALS, INC. (US) | 2010-07-13 | — | — | US | disclosed |
| US-7754712-B2 | Bridged N-cyclic sulfonamido inhibitors of gamma secretase | ELAN PHARMACEUTICALS, INC. (US) | 2010-07-13 | — | — | US | disclosed |
| US-20080090817-A1 | Bridged N-Cyclic Sulfonamido Inhibitors of Gamma Secretase | ELAN PHARMACEUTICALS, INC. | 2008-04-17 | — | — | US | disclosed |
| US-20080090817-A1 | Bridged N-Cyclic Sulfonamido Inhibitors of Gamma Secretase | ELAN PHARMACEUTICALS, INC. | 2008-04-17 | — | — | US | disclosed |
| US-20080090817-A1 | Bridged N-Cyclic Sulfonamido Inhibitors of Gamma Secretase | ELAN PHARMACEUTICALS, INC. | 2008-04-17 | — | — | US | disclosed |
| US-7345056-B2 | Bridged N-cyclic sulfonamido inhibitors of gamma secretase | ELAN PHARMACEUTICALS, INC. (US) | 2008-03-18 | — | — | US | disclosed |
| US-7345056-B2 | Bridged N-cyclic sulfonamido inhibitors of gamma secretase | ELAN PHARMACEUTICALS, INC. (US) | 2008-03-18 | — | — | US | disclosed |
| US-7345056-B2 | Bridged N-cyclic sulfonamido inhibitors of gamma secretase | ELAN PHARMACEUTICALS, INC. (US) | 2008-03-18 | — | — | US | disclosed |
| US-20070049612-A1 | Bridged N-Cyclic Sulfonamido Inhibitors of Gamma Secretase | ELAN PHARMACEUTICALS, INC. | 2007-03-01 | — | — | US | disclosed |
| US-20070049612-A1 | Bridged N-Cyclic Sulfonamido Inhibitors of Gamma Secretase | ELAN PHARMACEUTICALS, INC. | 2007-03-01 | — | — | US | disclosed |
| US-20070049612-A1 | Bridged N-Cyclic Sulfonamido Inhibitors of Gamma Secretase | ELAN PHARMACEUTICALS, INC. | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090817-A1 | Bridged N-Cyclic Sulfonamido Inhibitors of Gamma Secretase | BACE1, BACE2, PSEN1 | PSEN1 3/4885PSEN2 4/4885APH1B 6/4885 |
| US-20070049612-A1 | Bridged N-Cyclic Sulfonamido Inhibitors of Gamma Secretase | BACE1, BACE2, PSEN1 | PSEN1 3/4885PSEN2 4/4885APH1B 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.